The Global Fund announced a deal with generic pharmaceutical manufacturers to significantly slash the price of cutting–edge HIV drug.

The global fund, a partnership set up in 2002 to battle AIDS, TB and Malaria.

The improved pricing will allow governments in resource limited settings to expand limited settings to expand access to critical HIV services.

The three in one pill bands together the drugs tenofovir disoproxil fumarate, lamivudine and dolutegravir.

The Global Fund to Fight AIDS, Tuberculosis and Malaria, commonly known as the Global Fund, is an international financing organization that was established in 2002 to address the global health crises caused by HIV/AIDS, tuberculosis (TB), and malaria.

These three diseases have significant impacts on public health, particularly in low- and middle-income countries.

The Global Fund's primary objective is to mobilize and allocate funding to support programs and initiatives aimed at preventing, treating, and controlling these diseases.

Its work involves partnering with governments, non-governmental organizations, civil society groups, and the private sector to coordinate efforts to combat these diseases on a global scale.

The slashing of medicine prices for HIV is essential in dealing with the HIV menace. Discuss